Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 9/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.70 |
| ▸ | CLK1 | P49759 | 2/20 | 0.70 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.70 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.70 |
| ▸ | KIT | P10721 | 4/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768155 | 0.85 | MAP3K11 (0.72) | MAP3K11DYRK1AKITLRRK2AAK1 | |
| SCHEMBL722653 | 0.85 | MAP3K11 (0.78) | MAP3K11DYRK1AKITLRRK2AAK1 | |
| SCHEMBL720821 | 0.84 | MAP3K11 (0.79) | MAP3K11DYRK1AKITLRRK2AAK1 | |
| SCHEMBL721015 | 0.83 | MAP3K11 (0.70) | MAP3K11DYRK1AKITLRRK2AAK1 | |
| SCHEMBL3771111 | 0.82 | MAP3K11 (0.78) | MAP3K11DYRK1AKITLRRK2AAK1 | |
| SCHEMBL721017 | 0.82 | MAP3K11 (1.00) | MAP3K11DYRK1AKITLRRK2AAK1 | |
| SCHEMBL723899 | 0.82 | MAP3K11 (0.81) | MAP3K11DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3770116 | 0.82 | CLK1 (0.83) | DYRK1ACLK1DYRK2DYRK1BKIT | |
| SCHEMBL720896 | 0.81 | MAP3K11 (1.00) | MAP3K11DYRK1AKITLRRK2NTRK1 | |
| SCHEMBL3696023 | 0.81 | CLK1 (0.72) | DYRK1ACLK1DYRK2DYRK1BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-103153994-B | Bicyclic heteroaryl kinase inhibitor and using method | UNIVERSITY OF ROCHESTER (US) | 2016-02-10 | — | — | CN | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014085795-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| CN-103153994-A | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIV ROCHESTER | 2013-06-12 | — | — | CN | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885DYRK1A 339/4885CLK1 41/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | MAP3K11 45/4885DYRK1A 349/4885CLK1 75/4885 |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885DYRK1A 339/4885CLK1 41/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | MAP3K11 23/4885DYRK1A 339/4885CLK1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.